- Home
- GILD vs BTI Comparison
GILD vs BTI Comparison
Compare GILD & BTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- BTI
- Stock Information
- Founded
- GILD 1987
- BTI 1902
- Country
- GILD United States
- BTI United Kingdom
- Employees
- GILD N/A
- BTI N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- BTI Medicinal Chemicals and Botanical Products
- Sector
- GILD Health Care
- BTI Health Care
- Exchange
- GILD Nasdaq
- BTI Nasdaq
- Market Cap
- GILD 140.8B
- BTI 125.1B
- IPO Year
- GILD 1992
- BTI N/A
- Fundamental
- Price
- GILD $119.02
- BTI $57.42
- Analyst Decision
- GILD Buy
- BTI Strong Buy
- Analyst Count
- GILD 24
- BTI 2
- Target Price
- GILD $114.26
- BTI N/A
- AVG Volume (30 Days)
- GILD 6.4M
- BTI 5.2M
- Earning Date
- GILD 08-07-2025
- BTI 09-15-2025
- Dividend Yield
- GILD 2.65%
- BTI 5.32%
- EPS Growth
- GILD 496.80
- BTI N/A
- EPS
- GILD 5.01
- BTI 1.89
- Revenue
- GILD $28,863,000,000.00
- BTI $35,067,817,512.00
- Revenue This Year
- GILD $1.91
- BTI N/A
- Revenue Next Year
- GILD $3.75
- BTI $2.24
- P/E Ratio
- GILD $23.75
- BTI $30.44
- Revenue Growth
- GILD 3.81
- BTI N/A
- 52 Week Low
- GILD $72.89
- BTI $34.17
- 52 Week High
- GILD $121.83
- BTI $58.46
- Technical
- Relative Strength Index (RSI)
- GILD 60.91
- BTI 73.55
- Support Level
- GILD $108.54
- BTI $56.72
- Resistance Level
- GILD $121.83
- BTI $58.46
- Average True Range (ATR)
- GILD 2.53
- BTI 0.73
- MACD
- GILD 0.67
- BTI 0.15
- Stochastic Oscillator
- GILD 78.86
- BTI 84.96
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About BTI British American Tobacco Industries p.l.c. ADR
The third-largest tobacco company by volume, British American Tobacco sold 518 billion cigarettes in 2024. Its leading brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans in cigarettes. Its ownership of the Camel, Natural American Spirit, and Newport brands are limited to the US. In next-generation products, the company has the Vuse brand in vaping, Glo in heated tobacco, and Velo in modern oral tobacco. The company also owns a 22.9% stake in ITC limited, the largest Indian cigarette company.